Overcoming antigen loss in CAR T therapy with Vγ9Vδ2 CAR T-cells

Background: Vγ9Vδ2 T-cells demonstrate potent antitumor activity in vitro but, despite successful safety studies, the clinical benefit of Vγ9Vδ2 in adoptive cell therapy has been limited. One approach to enhance the therapeutic potential of Vγ9Vδ2 T-cells while maintaining their safety profile is ge...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Velasco Santiago, P. Aehnlich, T.M. Hulen, K.M. Jensen, G. Holmen Olofsson, Ö. Met, P. thor Straten
Format: Article
Language:English
Published: Elsevier 2025-06-01
Series:Immuno-Oncology and Technology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2590018825000139
Tags: Add Tag
No Tags, Be the first to tag this record!